This critical review considers the extensive research and development dedicated, in the last years, to a single polymer, the poly(ethylene 2,5-furandicarboxylate), usually simply referred to as PEF. PEF importance stems from the fact that it is based on renewable resources, typically prepared from C6 sugars present in biomass feedstocks, for its resemblance to the high-performance poly(ethylene terephthalate) (PET) and in terms of barrier properties even outperforming PET. For the first time synthesis, properties, and end-life targeting-a more sustainable PEF-are critically reviewed. The emphasis is placed on how synthetic roots to PEF evolved toward the development of greener processes based on ring open polymerization, enzymatic synthesis, or the use of ionic liquids; together with a broader perspective on PEF end-life, highlighting recycling and (bio)degradation solutions.

Glaucoma is a progressive optic neuropathy that is the second leading cause of preventable blindness worldwide, after cataract formation. A rise in the intraocular pressure (IOP) is considered to be a major risk factor for glaucoma and is associated with an abnormal increase of resistance to aqueous humour outflow from the anterior chamber. Glaucoma drainage devices have been developed to provide an alternative pathway through which aqueous humour can effectively exit the anterior chamber, thereby reducing IOP. These devices include the traditional aqueous shunts with tube-plate design, as well as more recent implants, such as the trabeculectomy-modifying EX-PRESS® implant and the new minimally invasive glaucoma surgery (MIGS) devices. In this review, we will describe each implant in detail, focusing on their efficacy in reducing IOP and safety profile. Additionally, a critical and evidence-based comparison between these implants will be provided. Finally, we will propose potential developments that may help to improve the performance of current devices.

No abstract

The present work aims at evaluating the potential gains derived from partially replacing calcium in resorbable β-tricalcium phosphate (β-TCP) by two different molar percentages of strontium (5, 10) and zinc (1, 2), concomitantly with a fixed molar percentage (0.5) of manganese. Synthetic granular composite bone filling grafts consisting of doped β-TCP and an alkali-free bioactive glass were prepared and implanted in ~4 mm diameter bone defects drilled in the calvaria of Wistar rats used as animal models. The animals were sacrificed after 9 weeks of implantation and the calvaria was excised. Non-manipulated bone was used as positive control, while empty defects were used as a negative control group. The von Kossa staining revealed an enhanced new bone formation with increasing doping levels, supporting the therapeutic effects exerted by the doping elements. The percentage of newly formed bone was similar when the defects were filled with autologous bone, BG (previous results) or 3TCP2/7BG, which indicates that the latter two are excellent candidates for replacement of autologous bone as bone regeneration material. This finding confirms that doping with suitable doses of therapeutic ions is a good strategy towards transposing the bone graft materials to biomedical applications in humans.

No abstract